Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 5/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2344406 | 0.93 | EPHX2 (0.40) | P2RY1MGLLMAPTCYP3A4ALDH1A1 | |
| SCHEMBL2347247 | 0.92 | ALDH1A1 (0.41) | P2RY1MGLLMAPTCYP3A4ALDH1A1 | |
| SCHEMBL2344992 | 0.91 | CYP3A4 (0.40) | MGLLCYP3A4ALDH1A1CYP2D6EPHX2 | |
| SCHEMBL2423710 | 0.88 | P2RY1 (0.40) | P2RY1MGLLMAPTEPHX2CACNA1H | |
| SCHEMBL2341595 | 0.87 | CYP3A4 (0.42) | MGLLCYP3A4ALDH1A1CYP2D6EPHX2 | |
| SCHEMBL2345174 | 0.87 | MGLL (0.40) | P2RY1MGLLMAPTEPHX2CACNA1H | |
| SCHEMBL2343479 | 0.86 | CYP3A4 (0.39) | P2RY1MGLLMAPTCYP3A4ALDH1A1 | |
| SCHEMBL2346280 | 0.86 | CYP3A4 (0.42) | P2RY1MGLLMAPTCYP3A4ALDH1A1 | |
| SCHEMBL2342336 | 0.86 | P2RY1 (0.41) | P2RY1MGLLMAPTEPHX2CACNA1H | |
| SCHEMBL2348397 | 0.83 | MGLL (0.49) | MGLLCYP3A4ALDH1A1CYP2D6EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358704-A1 | 7-azaspiro [3.5]nonane-7-carboxamide compounds as modulators of fatty acid amide hydrolase | Pfizer Inc. (US) | 2011-08-24 | — | — | EP | claimed |
| US-20100113465-A1 | 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS | PFIZER INC. | 2010-05-06 | — | — | US | claimed |
| WO-2010049841-A1 | 7-AZASPIRO [3.5] NONANE-7-CARBOXAMIDE COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | PFIZER INC. (US) | 2010-05-06 | — | — | WO | claimed |
| US-20260103492-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2026-04-16 | — | — | US | disclosed |
| US-12421281-B2 | Cyclosporine compositions and methods of use | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2025-09-23 | — | — | US | disclosed |
| US-20250205175-A1 | Anti-Aging Composition with mTOR inhibitor for Humans and Other Mammals | POSTREL RICHARD (US) | 2025-06-26 | — | — | US | disclosed |
| US-20250179121-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2025-06-05 | — | — | US | disclosed |
| US-20250152562-A1 | Compositions to Enhance and Extend Quality of Life | POSTREL RICHARD (US) | 2025-05-15 | — | — | US | disclosed |
| WO-2025085674-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ULCERATIVE COLITIS | BACAINN THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-12280019-B2 | Anti-aging therapy for humans and other mammals | POSTREL RICHARD (US) | 2025-04-22 | — | — | US | disclosed |
| US-12252556-B2 | Cyclosporine compositions and methods of use | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2025-03-18 | — | — | US | disclosed |
| EP-3996702-A1 | PIEZO AGONISTS FOR PREVENTING OR REVERTING ABNORMAL AMYLOID DEPOSITION | Itä-Suomen Yliopisto (FI) | 2022-05-18 | — | — | EP | disclosed |
| US-11331300-B2 | Reversing baldness through follicle regeneration | POSTREL RICHARD (US) | 2022-05-17 | — | — | US | disclosed |
| US-11318093-B2 | Dental topical anesthetic gel | PAC-DENT, INC. | 2022-05-03 | — | — | US | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| CN-114126617-A | Piezoelectric agonists for preventing or reversing abnormal amyloid deposition | 东芬兰大学 | 2022-03-01 | — | — | CN | disclosed |
| US-20100113465-A1 | 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS | PFIZER INC. | 2010-05-06 | — | — | US | disclosed |
| US-20100113465-A1 | 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS | PFIZER INC. | 2010-05-06 | — | — | US | disclosed |
| US-20100113465-A1 | 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS | PFIZER INC. | 2010-05-06 | — | — | US | disclosed |
| WO-2010049841-A1 | 7-AZASPIRO [3.5] NONANE-7-CARBOXAMIDE COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | PFIZER INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12252556-B2 | Cyclosporine compositions and methods of use | FPR2, FPR1, FPR3 | P2RY1 143/4885MGLL 3329/4885MAPT 4342/4885 |
| US-20260103492-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | ABCC1, SLC47A2, ABCB1 | P2RY1 667/4885MGLL 1607/4885MAPT 2556/4885 |
| US-12421281-B2 | Cyclosporine compositions and methods of use | FPR2, FPR1, FPR3 | P2RY1 295/4885MGLL 967/4885MAPT 4195/4885 |
| US-20100113465-A1 | 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS | FAAH, FAAH2, APEH | P2RY1 1237/4885MGLL 298/4885MAPT 2046/4885 |
| US-20250179121-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | FPR2, FPR1, FPR3 | P2RY1 143/4885MGLL 3329/4885MAPT 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.